Search by Drug Name or NDC

    NDC 50458-0141-01 INVOKANA 300 mg/1 Details

    INVOKANA 300 mg/1

    INVOKANA is a ORAL TABLET, FILM COATED in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Janssen Pharmaceuticals, Inc.. The primary component is CANAGLIFLOZIN.

    Product Information

    NDC 50458-0141
    Product ID 50458-141_004c990c-b658-432f-e063-6394a90aa93d
    Associated GPIs 27700020000330
    GCN Sequence Number 070792
    GCN Sequence Number Description canagliflozin TABLET 300 MG ORAL
    HIC3 C4D
    HIC3 Description ANTIHYPERGLYCEMIC-SOD/GLUC COTRANSPORT2(SGLT2) INH
    GCN 34441
    HICL Sequence Number 040171
    HICL Sequence Number Description CANAGLIFLOZIN
    Brand/Generic Brand
    Proprietary Name INVOKANA
    Proprietary Name Suffix n/a
    Non-Proprietary Name canagliflozin
    Product Type HUMAN PRESCRIPTION DRUG
    Dosage Form TABLET, FILM COATED
    Route ORAL
    Active Ingredient Strength 300
    Active Ingredient Units mg/1
    Substance Name CANAGLIFLOZIN
    Labeler Name Janssen Pharmaceuticals, Inc.
    Pharmaceutical Class P-Glycoprotein Inhibitors [MoA], Sodium-Glucose Cotransporter 2 Inhibitor [EPC], Sodium-Glucose Transporter 2 Inhibitors [MoA]
    DEA Schedule n/a
    Marketing Category NDA
    Application Number NDA204042
    Listing Certified Through 2024-12-31

    Package

    NDC 50458-0141-01 (50458014101)

    NDC Package Code 50458-141-01
    Billing NDC 50458014101
    Package 5 TABLET, FILM COATED in 1 BOTTLE (50458-141-01)
    Marketing Start Date 2013-03-29
    NDC Exclude Flag N
    Pricing Information N/A